Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Celgene announces takeover of Impact Biomedicines

Celgene announces takeover of Impact Biomedicines

8th January 2018

Celgene has announced the acquisition of Impact Biomedicines, a developer of innovative treatments for patients with complex cancers.

Under the terms of the agreement, Celgene will pay an upfront fee of approximately $1.1 billion (GBP 811.74 million), with up to $1.25 billion in fees contingent on regulatory approval milestones for future myelofibrosis therapies.

The deal will see Celgene take control of fedratinib, a highly selective JAK2 kinase inhibitor for the treatment of myelofibrosis and polycythemia vera, which has already been evaluated in 877 patients across 18 clinical trials.

Based on the reported risk-benefit profile of fedratinib from the JAKARTA-1 and JAKARTA-2 clinical trials, regulatory applications in myelofibrosis are planned later this year.

Nadim Ahmed, president for haematology and oncology at Celgene, said: "We believe fedratinib is uniquely positioned as a potential treatment for myelofibrosis and it provides strategic options for us to build leadership in this disease with luspatercept and other pipeline assets."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.